C12N 2795/10332
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2795/10332 (Use of virus as therapeutic agent, other than vaccine) appears on 65 US grants and 95 published applications in this corpus.
Search patents in C12N- Granted patents
- 65
- Published applications
- 95
- Assignees
- 46
- Inventors
- 146
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 3 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 4 |
| 2012 | 4 | 2 |
| 2013 | 1 | 4 |
| 2014 | 3 | 4 |
| 2015 | 2 | 1 |
| 2016 | 1 | 6 |
| 2017 | 5 | 2 |
| 2018 | 2 | 2 |
| 2019 | 1 | 3 |
| 2020 | 4 | 9 |
| 2021 | 3 | 16 |
| 2022 | 9 | 13 |
| 2023 | 1 | 1 |
| 2024 | 9 | 11 |
| 2025 | 11 | 3 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bacteriophages for treatment of tuberculosis31 Mar 2026US 12,589,127 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions comprising Propionibacterium acnes bacteriophages for treating acne17 Mar 2026US 12,576,024 B2Phi Therapeutics, Inc.
- Bacteriophages for the treatment of tuberculosis17 Mar 2026US 12,576,118 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Use of specific phages for the treatment of nontuberculosis mycobacteria (NTM) infections4 Nov 2025US 12,458,673 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Bacteriophage for modulating inflammatory bowel disease19 Aug 2025US 12,390,499 B2Biomx Ltd.
- Disposable personal care products composed of nonwoven fabrics coated with bacteriophages to prevent and reduce bacterially caused skin problems9 Jul 2026US 2026/0191922 A1Parallel Health, Inc.
- Staphylococcus phage compositions and cocktails thereof7 May 2026US 2026/0124259 A1Locus Biosciences, Inc.
- Bacteriophage compositions and methods for treatment of bacterial infections23 Apr 2026US 2026/0108570 A1The University of Chicago
- Plant disease control composition, plant disease control method, and use of organic silicone-based surfactant19 Mar 2026US 2026/0076375 A1Kaneka Corporation
- A carbomer hydrogel comprising a phage lysate for maintaining natural skin microflora and suppressing pathogenic bacteria26 Feb 2026US 2026/0053871 A1Fagofarma S.R.O.
Most cited
By later US patents
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system48US 5,688,501 AExponential Biotherapies, Inc. · 1997
- Sequence specific antimicrobials39US 10,660,943 B2The Rockefeller University · 2020
- Bacteriophage genotypically modified to delay inactivations by the host defense system31US 5,811,093 AExponential Biotherapies, Inc. · 1998
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic18US 5,766,892 AExponential Biotherapies, Inc. · 1998
- Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system15US 5,660,812 AExponential Biotherapies, Inc. · 1997